Rifampicin
- Generic Name
- Rifampicin
- Brand Names
- Isonarif, Rifadin, Rifamate, Rifater, Rofact
- Drug Type
- Small Molecule
- Chemical Formula
- C43H58N4O12
- CAS Number
- 13292-46-1
- Unique Ingredient Identifier
- VJT6J7R4TR
- Background
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericid...
- Indication
Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.
- Associated Conditions
- Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis
- Associated Therapies
- Antibacterial therapy
Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- KBP Biosciences
- Target Recruit Count
- 24
- Registration Number
- NCT04606537
- Locations
- 🇺🇸
QPS Missouri, Springfield, Missouri, United States
Evaluation of Effect of Rifampin on the Pharmacokinetics of Vonoprazan in Healthy Participants
- First Posted Date
- 2020-09-22
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Phathom Pharmaceuticals, Inc.
- Registration Number
- NCT04558216
- Locations
- 🇺🇸
PPD Development, LP, 7551 Metro Center Drive, Suite 200, Austin, Texas, United States
Fruquintinib CYP3A Inhibitor and Inducer Study
- Conditions
- Interventions
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- Hutchison Medipharma Limited
- Target Recruit Count
- 28
- Registration Number
- NCT04557397
- Locations
- 🇺🇸
WCCT, Cypress, California, United States
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels
- Conditions
- Interventions
- First Posted Date
- 2020-09-03
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT04537715
- Locations
- 🇪🇸
Onkologikoa, Donostia, Gipuzkoa, Spain
🇺🇸California Cancer Associates for Research and Excellence, Inc. (cCARE), Encinitas, California, United States
🇺🇸Northwestern University-Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States
Pharmacokinetics of Verinurad and Allopurinol in Combination With Cyclosporine and Rifampicin in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2020-08-31
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT04532918
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Phenotyping of High Dose Rifampicin
- Conditions
- Interventions
- First Posted Date
- 2020-08-25
- Last Posted Date
- 2021-08-17
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT04525235
- Locations
- 🇿🇦
TASK, Cape Town, South Africa
🇿🇦UCT lung institute, Cape Town, South Africa
Rosuvastatin Evaluation as a Tuberculosis Treatment Adjunct
- Conditions
- Interventions
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2020-08-07
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 154
- Registration Number
- NCT04504851
- Locations
- 🇺🇬
Joint Clinical Research Centre, Kampala, Uganda
🇻🇳Vietnam Military Medical University, Hanoi, Vietnam
🇵🇭Tropical Disease Foundation, Makati City, Philippines
Drug-drug Interaction Study of Gepotidacin
- Conditions
- Interventions
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2022-03-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 64
- Registration Number
- NCT04493931
- Locations
- 🇺🇸
GSK Investigational Site, Las Vegas, Nevada, United States
Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)
- Conditions
- Interventions
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2020-07-24
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 926
- Registration Number
- NCT04485156
- Locations
- 🇰🇷
Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine, Seoul, Korea, Republic of
A Study to Assess the Effects of Itraconazole and Rifampin on Lazertinib in Healthy Adult Participants
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2021-03-01
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 32
- Registration Number
- NCT04410094
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.